The vet to vet support service is designed to help vets in practice manage cancer cases
CVS Launches New Collaborative Cancer Care Service To Support First Opinion Veterinary Practices
2 weeks ago 
204 views
CVS has announced the launch of its new Collaborative Cancer Care service – a comprehensive oncology vet to vet support service offering designed to help all vets in practice manage cancer cases with greater confidence, clarity and compassion.
The service is now available across CVS practices and will be extended to non‑CVS veterinary practices from 1st February 2026. So that every vet, owner and patient, no matter where they are, can access this support.
The new service brings together the expertise of CVS’ Vet Oracle Teleoncology, Axiom Laboratories, and Finn Pathologists, providing a unified, clinically robust pathway to support the diagnosis, staging and treatment of oncology patients. By integrating teleoncology advice with advanced laboratory testing and specialist pathology capabilities, CVS aims to help vets deliver the best possible outcomes for pets diagnosed with cancer.
A collaborative, end‑to‑end oncology support offering
The Collaborative Cancer Care service has been designed to support first opinion vets through every stage of the oncology journey – from initial suspicion of cancer through diagnosis, treatment planning, ongoing case management and referral if appropriate.
The list of services available includes:
- An initial 20‑minute phone consultation with a member of the CVS Vet Oracle Teleoncology team, providing an early clinical overview and guidance immediately after lab results from Axiom or Finn indicate a suspicion or diagnosis of cancer.
- A tailored treatment plan, delivered as a detailed PDF report, including interpretation of laboratory findings, additional recommended diagnostic tests and markers, chemotherapy protocols and palliative care considerations.
- Follow‑up advice, accompanied by a written report, offering further guidance as treatment progresses, helping vets refine therapy plans and address clinical developments as they arise.
This collaborative model ensures that all veterinary teams and pets have access to real‑time specialist support without any geographical barrier. The compassionate and fully contextualised guidance they receive assists veterinary teams to have confident, informed and evidence-based conversations with owners, during what can be an emotionally challenging period.
There is a direct calendar booking link available for CVS vets only. This enables vets to upload clinical history, cytology findings and histopathology reports, to enable the Teleoncology team to provide more precise, case‑specific support from the outset.
Accessing the service
Following receipt of lab results from Axiom or Finn suggestive of cancer, vets can request a phone consultation with a CVS Vet Oracle Teleoncologist by contacting the laboratory teams directly on Axiom: 01626 355655 and Finn Pathologists: 01379 854180.
Alternatively, CVS vets can book a call using the Vet Oracle Teleoncology booking portal:
https://outlook.office.com/book/[email protected]/.
Expert oncology support, at your fingertips
CVS’ Vet Oracle Teleoncology is staffed by RCVS and EBVS® Specialists in Veterinary Oncology, Diplomates of the American College of Veterinary Internal Medicine, and ECVIM‑CA residency‑trained clinicians, ensuring that every recommendation is grounded in advanced, up‑to‑date oncology knowledge.
Cancer in pets is often unpredictable, and owners can find the diagnosis or suspicion of cancer both overwhelming and emotionally difficult. The teleoncology team provides individualised, empathetic, case‑specific advice following a thorough assessment of each patient’s medical history and diagnostic results. Guidance can be offered on staging, treatment options, chemotherapy protocols and potential toxicities and palliative care plans– all with the aim of empowering vets to deliver informed and compassionate care that align with the owners wishes.
Advanced laboratory and pathology capabilities
Finn Pathologists and Axiom Laboratories bring decades of diagnostic expertise to the Collaborative Cancer Care service.
Finn Pathologists, established over 30 years ago, has long been recognised for its leading histopathology capabilities. Its partnership with Aiforia Technologies has enabled the development of a new AI‑assisted model for more accurate assessment of Ki‑67 expression in canine mast cell tumours. This advanced method reduces subjectivity, increases consistency and provides more reliable prognostic information for vets and owners.
Axiom Laboratories, based in Devon with a team of more than 120 experts, delivers one of the UK’s most extensive and rapid diagnostic services. Both laboratories offer full histopathology services, including the routinely requested and clinically valuable Ki‑67 test.
A step forward for veterinary oncology support
By uniting teleoncology, laboratory expertise and specialist pathology insight, CVS’ new Collaborative Cancer Care service represents a significant advancement in the support available to first opinion veterinary teams managing oncology cases, wherever their geographic location or circumstances.
Sophie Keyte, Clinical Director of CVS Vet Oracle, said: “Cancer is one of the most difficult diagnoses for veterinary teams and pet owners to navigate. Our Collaborative Cancer Care service is designed to offer first opinion vets the reassurance of rapid access to expert oncology guidance at the moments they need it most. By bringing together teleoncology, pathology and laboratory expertise, we can support vets in making confident decisions and help ensure pets receive compassionate, well‑informed care throughout their cancer journey.”
Alex Aldridge, Director of CVS Laboratories, added: “This collaboration reflects our commitment to providing veterinary practices with the very best diagnostic insights and clinical support. Our teams at Axiom and Finn Pathologists are proud to contribute advanced testing – including our AI‑enhanced Ki‑67 assessment – to a service that empowers first opinion vets and ultimately helps more pets receive timely, high‑quality cancer care.”
CVS Group operates across small animal, farm animal, equine and laboratories, with over 500 veterinary practices and referral centres in the UK and Australia. CVS has invested £122 million in its sites, facilities, equipment and technology since the start of 2023, in addition to providing industry leading training and support, to give the best possible care to animals.
More from CVS UK Ltd
- Landmark feline cancer study reveals new genetic insights that could transform treatment options for cats
- CVS Equine referral hospitals deliver major cuts in isoflurane use and carbon emissions through innovative anaesthesia practices
- CVS launches Collaborative Care project to strengthen veterinary client engagement and clinical outcomes
- CVS introduces ‘Prescribing with Purpose’ to advance clinical quality and environmental stewardship in practice
- Chestergates Veterinary Specialists launches Specialist Dermatology Service